One potential solution to the Trump administration's more assertive posture on pharmaceutical pricing in benchmark countries like Australia is to raise the published list PBS price paid to manufacturers. Yet it could have unintended consequences.
A simple increase in published list prices could have unintended consequences
February 10, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News

